June 21, 2012
Researchers from Analysis Group’s Health Care Consulting practice have been invited to present at the 28th International Conference on Pharmacoepidemiology, convening Aug. 23 to 26 in Barcelona, Spain. Our professionals will deliver seven poster and podium presentations on a number of medical conditions, including asthma, cardiovascular diseases, hemophilia A, and schizophrenia.
Podium Presentations
The Impact of Omalizumab Initiation on Emergency Department Visits, Hospitalizations, and Corticosteroid Use in Patients with Uncontrolled Asthma Using High-Dose Inhaled Corticosteroids and Long-Acting Beta2-Agonists, codeveloped by an Analysis Group team including Senior Economist Marie-Hélène Lafeuille, Managing Principal and Chief Epidemiologist Mei Sheng Duh, and Vice President Patrick Lefebvre, along with researchers from Novartis Pharmaceuticals.
The Development and Validation of a Classification Algorithm for Prophylactic versus On-Demand Factor VIII Therapy in Patients with Hemophilia A, codeveloped by an Analysis Group team including Senior Economist Francis Vekeman, Associate Wendy Cheng, and Dr. Duh, along with researchers from Bayer HealthCare Pharmaceuticals.
Are Vasodilators of Value in the Care of Patients Hospitalized for Acute Heart Failure? codeveloped by an Analysis Group team including Dr. Duh, Mr. Vekeman, and Associate Adi Eldar-Lissai, along with researchers from Novartis Pharma AG and Temple University’s School of Medicine.
Poster Presentations
The Impact of Long-Acting Injectable versus Oral Antipsychotics on Hospitalization Rates in Patients with Schizophrenia: A Systematic Review and Meta-Analysis, coauthored by an Analysis Group team including Ms. Lafeuille, Economists Valerie Carter and Jason Dean, Dr. Duh, and Mr. Lefebvre, along with researchers from Janssen Scientific Affairs LLC.
The Impact of Long-Acting Injectable versus Oral Antipsychotics on Rehospitalization Rates and Emergency Room Visits among Relapsed Schizophrenia Patients, coauthored by an Analysis Group team including Ms. Lafeuille, Mr. Lefebvre, Vice President Christian Frois, and Dr. Duh, along with researchers from Janssen Scientific Affairs.
The Risk of Gastrointestinal Conditions among Patients with Atrial Fibrillation, coauthored by an Analysis Group team including Economist Katherine Dea, Dr. Duh, and Mr. Lefebvre, along with researchers from Janssen Scientific Affairs.
Chronic Heart Failure in the Elderly: Clinical Characteristics and Resource Utilization Following Initial Hospitalization, coauthored by an Analysis Group team including Manager Caroline Korves, Dr. Eldar-Lissai, Associate Kristina Chen, and Dr. Duh, along with researchers from Novartis Pharmaceuticals.